Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: The renaissance of an old antibiotic

Clinical Microbiology and Infection

Volumn 11, Issue 2, 2005, Pages 115-121

  Michalopoulos, A S ^a   Tsiodras, S ^a   Rellos, K ^a   Mentzelopoulos, S ^a   Falagas, Matthew E ^a,b,c  

^a HENRY DUNANT HOSPITAL   (Greece)

^b Alfa HealthCare   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acinetobacter baumannii; Colistin; ICU acquired infection; Infection; Nosocomial; Pseudomonas aeruginosa

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; COLISTIN; GLYCOPEPTIDE; INOTROPIC AGENT; METRONIDAZOLE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE; SULTAMICILLIN;

ACINETOBACTER BAUMANNII; ADULT; AGED; ANTIBIOTIC RESISTANCE; APNEA; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; CASE STUDY; CLINICAL ARTICLE; CRITICAL ILLNESS; DRUG EFFICACY; DRUG SAFETY; GRAM NEGATIVE BACTERIUM; GREECE; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; LENGTH OF STAY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; MUSCLE WEAKNESS; NEPHROTOXICITY; PARESTHESIA; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; RISK FACTOR; SEPTIC SHOCK; TREATMENT FAILURE; TREATMENT OUTCOME; VERTIGO;

ACINETOBACTER BAUMANNII; BACILLI; NEGIBACTERIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 13844311296     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.01043.x     Document Type: Article

References (29)

1. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 432-474.
2. Livermore D. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34: 634-640.
3. Catchpole CR, Andrews JM, Brenwald N, Wise R. A reassessment of the in vitro activity of colistin sulfomethate sodium. J Antimicrob Chemother 1997; 39: 255-260.
4. Horton J, Pankey GA. Polymyxin B, colistin and sodium colistimethate. Med Clin North Am 1982; 66: 135-142.
5. Conway SP, Pond MN, Watson A, Etherington C, Robey HL, Goldman MH. Intravenous colistin sulfomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 1997; 52: 987-993.
6. Beringer P. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med 2001; 7: 434-440.
7. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36: 1111-1118.
8. Levin AS, Baron AA, Penco J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-1011.
9. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant Gram-negative bacteria. Antimicrob Agents Chemother 2003; 47: 2659-2662.
10. Markou N, Apostolakos H, Koumoudiou C et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003; 7: 78-83.
11. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II. a severity of disease classification system. Crit Care Med 1985; 13: 818-829.
12. Rello J, Paiva JA, Baraibar J et al. International conference for the development of consensus on the diagnosis and treatment of ventilator-associated pneumonia. Chest 2001; 120 955-970.
13. Gaynes RP, Horan TC. Surveillance of nosocomial infections. Appendix A. CDC definitions of nosocomial infections. In: Mayhall, CG, ed. Hospital epidemiology and infection control. Baltimore: Williams & Wilkins 1996, 1-14.
14. Vincent JL, de Mendonça A, Cantraine F et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicentric, prospective study. Crit Care Med 1998; 26: 1793-1800.
15. Clermont G, Acker CG, Angus DC, Sirio CA, Pinsky MR, Johnson JP. Renal failure in the ICU: comparison of the impact of acute renal failure and end-stage renal failure on ICU outcomes. Kidney Int 2002; 62: 986-996.
16. Uchino S, Doig GS, Bellomo R et al. Diuretics and mortality in acute renal failure. Crit Care Med 2004; 32: 1669-1677.
17. De Mendonca A, Vincent JL, Suter PM et al. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intens Care Med 2000; 26: 915-921.
18. Michalopoulos AS, Geroulanos S, Mentzelopoulos SD. Determinants of candidemia and candidemia-related death in cardiothoracic intensive care unit patients. Chest 2003; 124: 2244-2255.
19. Annane D, Aegerter P, Jars-Guincestre MC, Giodet B, CUB-Rea Network. Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med 2003; 168: 165-172.
20. Bercault N, Boulain T. Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. Crit Care Med 2001; 29 2303-2309.
21. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of nosocomial candidemia on outcome in critically ill patients. Am J Med 2002; 15: 480-485.
22. Giamarellou H. Therapeutic guidelines for Pseudomonas aeruginosa infections. Int J Antimicrob Agents 2000; 16: 103-106.
23. Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45: 781-785.
24. Koch-Weser G, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Ann Intern Med 1970; 72: 857-868.
25. Rynn C, Wooton M, Bowker KE, Holt HA, Reeves DS. In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics. Clin Microbiol Infect 1999; 5: 32-36.
26. Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. Synergistic activity of colistin and ceftazidime against multiantibiotic resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003; 47: 905-909.
27. Giamarellos-Bourboulis EJ, Sambatakou H, Galani I, Giamarellou H. In vitro interaction of colistin and rifampin on multidrug resistant Pseudomonas aeruginosa. J Chemother 2003; 15: 235-238.
28. Denton M, Kerr K, Mooney L et al. Transmission of colistin resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol 2002; 34: 257-261.
29. Drumi W. Prophylactic use of continuous renal replacement therapies in patients with normal renal function. Am J Kidney Dis 1996; 28: S114-S120.